Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Glycoursodeoxycholic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 1/20 | 0.74 |
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.67 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.67 |
| ▸ | GPBAR1 | Q8TDU6 | 11/20 | 0.83 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 5/20 | 0.83 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.83 |
| ▸ | SLC10A2 | Q12908 | 4/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.71 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycoursodeoxycholic Acid SCHEMBL7206212 | 1.00 | GPBAR1 (0.83) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| Glycoursodeoxycholic Acid SCHEMBL29366725 | 1.00 | GPBAR1 (0.83) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| Glycoursodeoxycholic Acid SCHEMBL2020307 | 0.99 | GPBAR1 (0.82) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| Glycoursodeoxycholic Acid SCHEMBL178105 | 0.98 | GPBAR1 (0.83) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| Glycoursodeoxycholic Acid SCHEMBL935341 | 0.91 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| Glycoursodeoxycholic Acid SCHEMBL9151495 | 0.91 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| Glycoursodeoxycholic Acid SCHEMBL59881 | 0.91 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| Glycoursodeoxycholic Acid SCHEMBL12917601 | 0.91 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| Glycochenodeoxycholate SCHEMBL236354 | 0.91 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2NR3C1 | |
| SCHEMBL19104663 | 0.91 | GPBAR1 (0.86) | GPBAR1NR1H4ABCB11ENPP2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 643 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139227-A1 | ADIPOSE-DERIVED REGENERATIVE CELL PREPARATIONS | BLUE CELL THERAPEUTICS APS (DK) | 2026-05-21 | — | — | US | claimed |
| EP-4701625-A2 | FORMULATION OF THERAPEUTIC AGENTS FOR IMPROVED PERMEATION | Vivtex Corporation (US) | 2026-03-04 | — | — | EP | claimed |
| EP-4651897-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | Syntis Bio, Inc. (US) | 2025-11-26 | — | — | EP | claimed |
| WO-2025224448-A1 | STABLE BIORELEVANT COMPOSITIONS AND MEDIA FOR IN VITRO TESTING | BIORELEVANT.COM LIMITED (GB) | 2025-10-30 | — | — | WO | claimed |
| CN-120053459-A | Stable meloxicam pharmaceutical composition and preparation method thereof | 扬子江药业集团有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-119970641-A | Nonaqueous preparation with controllable release behavior and application thereof | 中国科学院上海药物研究所 | 2025-05-13 | — | — | CN | claimed |
| WO-2025081956-A1 | LACTOBACILLUS PARACASEI VB306 AND USE THEREOF | 杭州微致生物科技有限公司 | 2025-04-24 | — | — | WO | claimed |
| WO-2025055998-A1 | BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS VB301 AND USE THEREOF | 杭州微致生物科技有限公司 | 2025-03-20 | — | — | WO | claimed |
| CN-117448198-B | Bifidobacterium animalis subspecies VB301 and application thereof | 杭州微致生物科技有限公司 | 2025-03-11 | — | — | CN | claimed |
| WO-2024226846-A2 | FORMULATION OF THERAPEUTIC AGENTS FOR IMPROVED PERMEATION | VIVTEX CORPORATION (US) | 2024-10-31 | — | — | WO | claimed |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION | 2009-10-29 | — | — | US | claimed |
| WO-2009129470-A2 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION (US) | 2009-10-22 | — | — | WO | claimed |
| US-20080050842-A1 | METHOD OF VISUALIZATION AND QUANITIFICATION OF BIOPOLYMER MOLECULES IMMOBILIZED ON SOLID SUPPORT | GOLOVLEV VALERI V | 2008-02-28 | — | — | US | claimed |
| EP-1608392-A4 | PAPANICOLAU STAINING PROCESS | CYTYC CORP (US) | 2007-09-05 | — | — | EP | claimed |
| US-7186522-B2 | Using detergents to reduce artifacts during staining of biological samples; medical diagnostics and cervical cancer | CYTYC CORPORATION (US) | 2007-03-06 | — | — | US | claimed |
| US-20070003998-A1 | Papanicolau staining process | THIRD WAVE TECHNOLOGIES, INC. | 2007-01-04 | — | — | US | claimed |
| EP-1608392-A2 | PAPANICOLAU STAINING PROCESS | Cytyc Corporation (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050145490-A1 | Reagent includes an oxidoreductase that reacts with the blood component (glucose,lactic acid, uric acid, cholesterol etc.) and potassium ferricyanide mediator, detecting a redox current generated by the redox reaction by the working electrode and the counter electrode; correct an effect of a hematocrit | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2005-07-07 | — | — | US | claimed |
| WO-2004086945-A2 | PAPANICOLAU STAINING PROCESS | CYTYC CORPORATION (US) | 2004-10-14 | — | — | WO | claimed |
| US-20040191854-A1 | Papanicolau staining process | CYTYC CORPORATION | 2004-09-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139227-A1 | ADIPOSE-DERIVED REGENERATIVE CELL PREPARATIONS | CXCL12, FGF2, FABP4 | NR3C1 131/4885CA1 4847/4885CA2 3775/4885 |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | DPM1, ERG28, CYP51A1 | NR3C1 2341/4885CA1 2808/4885CA2 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.